Qrons (QRON) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 13, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-55800
Entity Registrant Name	QRONS INC.
Entity Central Index Key	0001689084
Entity Tax Identification Number	81-3623646
Entity Incorporation, State or Country Code	WY
Entity Address, Address Line One	50 Battery Place
Entity Address, Address Line Two	#7T
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10280
City Area Code	(212)
Local Phone Number	945-2080
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		13,289,789

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 84,383	$ 57,632
Prepaid expenses	4,000
Total current assets	88,383	57,632
TOTAL ASSETS	88,383	57,632
Current liabilities
Accounts payable and accrued liabilities	63,200	49,059
Accounts payable and accrued liabilities – related party	41,261	43,768
Demand loans, related party	50,000	50,000
Advances from related party	286,000	286,000
Unsecured short-term advances	100,000	100,000
Convertible notes – related party, net of debt discount	25,000	25,000
Convertible notes, net of debt discount	66,126	43,636
Derivative liabilities	345,647	154,485
Total current liabilities	977,234	751,948
Total liabilities	977,234	751,948
Stockholders’ deficit
Series A Preferred stock: $0.001 par value; 10,000 shares authorized; 2,000 shares issued and outstanding	2	2
Common stock, $0.0001 par value: 100,000,000 shares authorized; 13,289,789 shares issued and outstanding	1,329	1,329
Additional paid-in capital	7,043,996	7,037,796
Accumulated deficit	(7,934,178)	(7,733,443)
Total stockholders’ deficit	(888,851)	(694,316)
TOTAL LIABILITIES & STOCKHOLDERS’ DEFICIT	$ 88,383	$ 57,632

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Series A Preferred Shares, par value	$ 0.001	$ 0.001
Series A Preferred Shares, authorized	10,000	10,000
Series A Preferred Shares, shares issued	2,000	2,000
Series A Preferred Shares, shares outstanding	2,000	2,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,289,789	13,289,789
Common stock, shares outstanding	13,289,789	13,289,789

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Net sales
Operating expenses:
Research and development expenses	11,350	2,891	23,186	174,459
Professional fees	8,300	6,893	23,940	30,517
General and administrative expenses	23,148	3,805	34,035	27,551
Total operating expenses	42,798	13,589	81,161	232,527
Income (loss) from operations	(42,798)	(13,589)	(81,161)	(232,527)
Other income (expense)
Interest expense	(111,758)	(12,814)	(122,744)	(27,098)
Change in derivative liabilities	189,130	9,672	3,170	2,762
Total other income (expense)	77,372	(3,142)	(119,574)	(24,336)
Net income (loss)	$ 34,574	$ (16,731)	$ (200,735)	$ (256,863)
Net income (loss) per common share - basic	$ 0	$ 0	$ (0.02)	$ (0.02)
Net income (loss) per common share - diluted	$ 0	$ 0	$ (0.01)	$ (0.02)
Weighted average shares outstanding
Basic	13,089,789	13,089,789	13,089,789	13,089,789
Diluted	17,610,815	17,610,815	17,610,815	17,610,815

Condensed Statement of Changes

Condensed Statement of Changes in Stockholders Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 2	$ 1,309	$ 6,561,047	$ (7,070,480)	$ (508,122)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019	2,000	13,089,789
Stock options granted to non-employees as research and development costs			67,554		67,554
Net loss for the year				(240,132)	(240,132)
Shares, Outstanding, Ending Balance at Mar. 31, 2020	2,000	13,089,789
Ending balance, value at Mar. 31, 2020	$ 2	$ 1,309	6,632,001	(7,310,612)	(677,300)
Warrants exercised associated with private placement			3,400		3,400
Beginning balance, value at Dec. 31, 2019	$ 2	$ 1,309	6,561,047	(7,070,480)	(508,122)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019	2,000	13,089,789
Net loss for the year					(256,863)
Shares, Outstanding, Ending Balance at Jun. 30, 2020	2,000	13,089,789
Ending balance, value at Jun. 30, 2020	$ 2	$ 1,309	6,661,718	(7,327,343)	(664,314)
Beginning balance, value at Mar. 31, 2020	$ 2	$ 1,309	6,632,001	(7,310,612)	(677,300)
Shares, Outstanding, Beginning Balance at Mar. 31, 2020	2,000	13,089,789
Stock options granted to non-employees as research and development costs			29,717		29,717
Net loss for the year				(16,731)	(16,731)
Shares, Outstanding, Ending Balance at Jun. 30, 2020	2,000	13,089,789
Ending balance, value at Jun. 30, 2020	$ 2	$ 1,309	6,661,718	(7,327,343)	(664,314)
Beginning balance, value at Dec. 31, 2020	$ 2	$ 1,329	7,037,796	(7,733,443)	(694,316)
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	2,000	13,289,789
Stock options granted to non-employees as research and development costs			3,100		3,100
Net loss for the year				(235,309)	(235,309)
Shares, Outstanding, Ending Balance at Mar. 31, 2021	2,000	13,289,789
Ending balance, value at Mar. 31, 2021	$ 2	$ 1,329	7,040,896	(7,968,752)	(926,525)
Beginning balance, value at Dec. 31, 2020	$ 2	$ 1,329	7,037,796	(7,733,443)	(694,316)
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	2,000	13,289,789
Net loss for the year					(200,735)
Shares, Outstanding, Ending Balance at Jun. 30, 2021	2,000	13,289,789
Ending balance, value at Jun. 30, 2021	$ 2	$ 1,329	7,043,996	(7,934,178)	(888,851)
Beginning balance, value at Mar. 31, 2021	$ 2	$ 1,329	7,040,896	(7,968,752)	(926,525)
Shares, Outstanding, Beginning Balance at Mar. 31, 2021	2,000	13,289,789
Stock options granted to non-employees as research and development costs			3,100		3,100
Net loss for the year				34,574	34,574
Shares, Outstanding, Ending Balance at Jun. 30, 2021	2,000	13,289,789
Ending balance, value at Jun. 30, 2021	$ 2	$ 1,329	$ 7,043,996	$ (7,934,178)	$ (888,851)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash Flows From Operating Activities
Net loss	$ (200,735)	$ (256,863)
Adjustments to reconcile net loss to net cash (used by) operating activities:
Stock options issued for research and development expense	6,200	97,271
Warrants granted as financing costs		3,400
Non cash interest expense	94,332
Accretion of debt discount	22,490	17,321
Change in derivative liabilities	(3,170)	(2,762)
Changes in operating assets and liabilities:
(Increase) decrease prepaid expenses	4,000	(48,614)
(Decrease) increase accounts payable and accrued liabilities	14,141	(56,048)
(Decrease) increase accounts payable and accrued liabilities, related party	(2,507)	4,569
Net cash (used by) operating activities	(73,249)	(144,498)
Cash Flows From Investing Activities
Net cash provided from (used by) investing activities
Cash Flows From Financing Activities
Proceeds from convertible notes	100,000	10,000
Proceeds from related party advances		76,000
Net cash provided from financing activities	100,000	86,000
Increase (decrease) in cash and cash equivalents	26,751	(58,498)
Cash at beginning of year	57,632	67,025
Cash at end of period	84,383	8,527
SUPPLEMENTAL DISCLOSURES
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES
Derivative liability associated with debt discount	51,009	7,915
Derivative liability associated with warrants	$ 143,323

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Note 1 – Description of Business and Basis of Presentation Organization and Nature of Business: Qrons Inc. (“Qrons” or the “Company”) was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. On July 6, 2017, the board of directors and a majority of the Company’s shareholders approved an amendment to the Company’s Articles of Incorporation to change the name of the Company from “BioLabMart Inc.” to “Qrons Inc.” On August 8, 2017, the Company filed Amended Articles of Incorporation with the State of Wyoming to effectuate such name change. The Company’s common stock was approved by the Financial Industry Regulatory Authority (“FINRA”) for quotation on the OTC pink sheets under the symbol “BLMB” as of July 3, 2017. FINRA announced the Company’s name change to Qrons Inc. on August 9, 2017. The new name and symbol change to “QRON” for the OTC Market was effective August 10, 2017. The Company’s common stock was upgraded from the Pink Market and commenced trading on the OTCQB Venture Market on August 12, 2019. The Company is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies to combat neuronal diseases, which are an enormous social and economic burden on society. The Company seeks to engage in strategic arrangements with companies and institutions that are developing breakthrough technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. The Company’s search is currently focused on researchers based in Israel, a country which is world-renowned for biotech innovations. The Company’s principal executive office is located at 50 Battery Place, #7T, New York, New York 10280.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Financial Statement Presentation: In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and six-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Fiscal Year End: Use of Estimates: Cash Equivalents: Research and Development Costs: Research and Development 23,186 174,459 Advertising and Marketing Costs: 15,000 23,500 Related Parties Stock-Based Compensation and Other Share-Based Payments Compensation - Stock Compensation Fair Value of Financial Instrument ASC 820, Fair Value Measurements Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of June 30, 2021: Liabilities Derivative liabilities $ $ $ 345,647 As of December 31, 2020: Liabilities Derivative liabilities $ - $ - $ 154,485 Warrants Derivatives and Hedging Income taxes Income Taxes Basic and Diluted Loss Per Share Earnings Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the three and six months ended June 30, 2021 and 2020 include potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because the Company reported net income in the current three months ended June 30, 2021. As a result, the computations of net loss per share for each period reflected both basic and fully diluted loss per share. The table below reflects the potentially dilutive securities June 30, December 31, Research warrants at 3% of issued and outstanding shares 398 694 398 694 Convertible notes 634,966 445,400 Series A preferred shares 700 700 Stock options vested 3,191,666 3,243,333 Stock options not yet vested - 33,333 Stock purchase warrants 295,000 180,000 Total 4,521,026 4,301,460 New Accounting Pronouncements

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 3 – Going Concern The Company has experienced net losses to date and has not generated revenues from operations. While the Company raised proceeds of $ 100,000 211,000 The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty. Covid-19 Pandemic The COVID-19 pandemic has had an adverse impact on the research and development of our product candidates. Research facilities at Dartmouth were subject to closures as well as laboratories at Ariel in Israel during fiscal 2020. This resulted in our discontinuing our research at these Universities and was part of our decision to adjust our research to be collaborative and to seek aligning with third parties to advance our expanded goals. We do not currently know the full extent of potential delays of research in the future as a result of the continuing pandemic restrictions. COVID-19 has also caused significant disruptions to the global financial markets, which severely impacts our ability to raise additional capital. We terminated our employees in April 2020 in an effort to conserve resources as we evaluate our business development efforts. The ultimate impact on us and our research relationships is currently uncertain. We may be required to further reduce operations or cease operations if we are unable to finance our operations. Management is actively monitoring the situation but given the daily evolution of the COVID-19 outbreak, the Company is not able to fully estimate the effects of the COVID-19 outbreak on its planned operations or financial condition in the next 12 months. However, while significant uncertainty remains, the Company believes it is likely that the COVID-19 outbreak will have a negative impact on its ability to raise additional financing and will result in delays as it continues to impact the Company’s workforce and its collaborative development efforts.

Convertible Note _ Related Part

Convertible Note – Related Party and Derivative Liabilities	6 Months Ended
	Jun. 30, 2021
Convertible Note Related Party And Derivative Liabilities
Convertible Note – Related Party and Derivative Liabilities	Note 4 – Convertible Note – Related Party and Derivative Liabilities On September 1, 2016, the Company entered into a convertible debenture agreement with CubeSquare, LLC (“CubeSquare”), of which its Chief Executive Officer is the managing partner and its President is a 25 10,000 8 (i) $0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender On September 29, 2017, the Company and CubeSquare amended Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018; on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019; on November 6, 2019, the Company further amended Note 1 to extend the maturity date to September 1, 2020; and on October 30, 2020, the Company further amended Note 1 to extend the maturity date to September 1, 2021, under the same terms and conditions. On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $ 15,000 8 Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare. The Company analyzed the amendment to Note 1 and Note 2 under ASC 815-10-15-83 and concluded that these two convertible Notes meet the definition of a derivative. The Company estimated the fair value of the derivative at each report date using the Black-Scholes valuation model to value the derivative liability related to the variable conversion rate. The carrying value of these convertible notes June 30, December 31, Face value of certain convertible notes $ 25,000 $ 25,000 Carrying value $ 25,000 $ 25,000 Schedule of interest on the convertible note Three Months ended Six Months ended June 30, June 30, 2021 2020 2021 2020 Interest on the convertible notes $ 499 $ 501 $ 992 $ 1,003 As of June 30, 2021 and December 31, 2020, the unpaid interest balance under Accounts payable and accrued liabilities – related party was $ 8,441 7,449 As a result of the application of ASC 815, the fair value of the derivative liability associated with the conversion feature Balance at December 31, 2019 $ 37,182 Change in fair value 24,500 Balance at December 31, 2020 61,682 Balance at December 31, 2020 61,682 Change in fair value (26,862 ) Balance at June 30, 2021 $ 34,820 The fair value at the commitment and re-measurement dates Commitment Date December 31, 2020 June 30, 2021 Expected dividends 0 0 0 Expected volatility 101% ~103% 316% ~ 333% 78% ~ 115% Expected term 0.92 ~ 1 year 0.74 year 0.25 year Risk free interest rate 1.33% 0.09% 0.05%

Convertible Note and Derivative

Convertible Note and Derivative Liabilities	6 Months Ended
	Jun. 30, 2021
Convertible Note And Derivative Liabilities
Convertible Note and Derivative Liabilities	Note 5 – Convertible Note and Derivative Liabilities (1) 8% Convertible notes with warrants issued in December 2019 and February 2020 In December 2019, we issued and sold in a private offering 8 70,000 convertible into shares of our common stock at a conversion price (the “Conversion Price”) for each share of common stock equal to the lesser of: (a) $0.50, (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable Notice of Conversion; and (c) so long as lower than (a) or (b), such price per share of common stock as the Company and the holder may agree from time to time. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00. On February 19, 2020 we issued and sold in a private offering 8 10,000 Such notes are convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) such other as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 10,000 shares of common stock at an exercise price of $1.00. The carrying value of these convertible note June 30, December 31, Face value of certain convertible notes $ 80,000 $ 80,000 Less: unamortized discount (18,600 ) (36,364 ) Carrying value $ 61,400 $ 43,636 Interest expenses associated with the convertible notes Three Months ended Six Months ended June 30, June 30, 2021 2020 2021 2020 Amortization on debt discount $ 8,931 $ 8,931 $ 17,764 $ 18,750 Interest on the convertible notes 1,895 1,895 2,569 3,381 Total $ 10,826 $ 10,826 $ 20,333 $ 22,131 As of June 30, 2021 and December 31, 2020, the unpaid interest balance under Accounts payable and accrued liabilities was $ 9,942 7,373 The convertible notes qualify for derivative accounting and bifurcation under ASC 815. The derivative liability of the $ 80,000 72,689 As a result of the application of ASC 815, as of June 30, 2021 and 2020, the fair value of the derivative liability associated with the conversion feature Balance at December 31, 2019 $ 52,185 Derivative addition associated with convertible notes 7,915 Change in fair value 32,703 Balance at December 31, 2020 92,803 Balance at December 31, 2020 92,803 Change in fair value 22,912 Balance at June 30, 2021 $ 115,715 The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities Commitment Date December 31, 2020 June 30, 2021 Expected dividends 0 0 0 Expected volatility 154% ~173% 280% ~296% 199%~358% Expected term 2.10 years 1.05 ~ 1.25 years 0.5 ~ 0.64 years Risk free interest rate 1.42 ~ 1.65% 0.10% 0.06% (2) 8% Convertible note with warrants issued on June 15, 2021 On June 15, 2021, the Company entered into a note purchase agreement with Quick Capital, LLC (“Quick Capital”) pursuant to which the Company issued a twelve-month convertible promissory note in the principal amount of $115,000 for a $100,000 investment (the “Note”), which included an original issuance discount of 10% and a $3,500 credit for legal and transaction costs. In connection with this convertible note issuance, Quick Capital was also issued a five-year warrant (the “Warrant”) to purchase up to an aggregate of 115,000 shares of the Company’s common stock at an exercise price of $1.00 per share (the “Warrant Shares”) subject to adjustments for dilutive issuances at lower prices. The Note is convertible into shares of common stock at a conversion price of $0.50 per share. If delivery of the Conversion Shares is not timely made, the Company is obligated to pay Quick Capital $2,000 for each day that the delivery is late as liquidated damages. The conversion price of the Note will be reduced if the Company issues common stock or grants derivative securities for consideration at a price less than the conversion price to the amount of the consideration of such dilutive issuance (“full ratchet reset”). The Note may not be prepaid. The Company is subject to significant cash penalties if the Company defaults on the notes or in the event shares are not issued timely when a notice of conversion is provided. If an event of default occurs, the Note will become immediately due and payable in an amount equal to 150% of the then outstanding principal amount of the Note plus any interest or amounts owing to Quick Capital. The default provisions are based on the type of default and include a penalty of 50% of the principal plus accrued interest due (the “Default Sum”) and a parity value of the Default Sum based on the effective conversion of the Note on the date of payment of the default and the maximum stock value during the period between the default date and the payment date. The Company valued the embedded default derivative liability of the Note and the Warrant liability, including the full ratchet reset feature, using Monte Carlo models. The carrying value of the Note is as follows: June 30, June 15, Face value of certain convertible notes $ 115,000 $ 115,000 Less: unamortized discount (110,274 ) (115,000 ) Carrying value $ 4,726 $ - Interest expenses associated with the conversion is as follows: Three Months ended Six Months ended June 30, June 30, 2021 2020 2021 2020 Amortization on debt discount $ 4,726 $ $ 4,726 $ Day one loss associated with derivative liability 79,332 79,332 Interest on the convertible notes 378 - 378 - Total $ 84,436 $ - $ 84,436 $ - (2) 8% Convertible note with warrants issued on June 15, 2021 As a result of the application of ASC 815 as of June 30, 2021 and June 15, 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows: Derivative liability associated with convertible note on commitment date $ 51,009 Derivative liability associated with warrants on commitment date 143,323 Derivative liability at June 15, 2021 194,332 Derivative liability at June 15, 2021 194,332 Change in fair value – convertible note 1,707 Change in fair value – warrants (927 ) Balance at June 30, 2021 $ 195,112 The fair value at the commitment and re-measurement Convertible note: Commitment Date June 30, Expected dividends 0 0 Expected volatility 307.10 % 312.60 % Expected term 1 years 0.96 years Risk free interest rate 0.18 % 0.23 % Warrants; Commitment Date June 30, Expected dividends 0 0 Expected volatility 201.70 % 200.60 % Expected term 5 years 4.96 years Risk free interest rate 0.65 % 0.66 %

Unsecured Short-Term Advance fr

Unsecured Short-Term Advance from Third Party	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Unsecured Short-Term Advance from Third Party	Note 6 – Unsecured Short-Term Advance from Third Party On June 20, 2019, the Company received $ 100,000

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 7 – Related Party Transactions (1) Demand Loan from related party On May 1, 2019, the Company issued a promissory note (the “Note”) to CubeSquare in the principal amount of $ 50,000 8 997 1,983 998 1,995 8,657 6,674 (2) Advances from Related Parties During the year ended December 31, 2019, the Company received $ 135,000 70,000 On August 20, 2019, the Company received $ 50,000 21,000 During the year ended December 31, 2020, the Company received $ 10,000 (3) Others Jonah Meer, the Company’s Chief Executive Officer, made payments to various vendors during the years ended December 31, 2019 and 2020. The balance payable to Mr. Meer of $ 22,993 28,475 During the year ended December 31, 2019, Ido Merfeld, the Company’s President, made payments to various vendors in the aggregate amount of $ 1,169 1,169

License and Research Funding Ag

License and Research Funding Agreement	6 Months Ended
	Jun. 30, 2021
License And Research Funding Agreement
License and Research Funding Agreement	Note 8 – License and Research Funding Agreement Royalty Agreement Ariel Scientific Innovation Ltd On November 30, 2019, the Company entered into a royalty and license fee sharing agreement (the “Royalty Agreement”) with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, in Ariel, Israel (“Ariel”), which, among other things, superseded and terminated the original license and research funding agreement, dated December 14, 2016, as amended, between the Company and Ariel (the “License Agreement”). Upon the occurrence of an Exit Event, as such term is described in the Royalty Agreement, including an underwritten public offering of the Company’s shares with proceeds of at least $25 million, a consolidation, merger or reorganization of the Company, and a sale of all or substantially all of the shares and/or the assets of the Company, Ariel has the right to require the Company to issue up to 3% of the then issued and outstanding shares of its common stock. The issuance of any such shares in the future will result in dilution to the interests of other stockholders. In consideration for the parties’ agreement to terminate the License Agreement and for future general scientific collaboration between the parties, the Company agreed to pay Ariel a royalty of 1.25% of net sales (as defined in the Royalty Agreement) of products sold by the Company, or its affiliates and licensees for fifteen years from the first commercial sale in a particular country. Services agreements which the Company had with Ariel related to laboratory access, molecular biology and neurobiology research, and other services terminated during the year ended December 31, 2020. During 2020, Ariel refunded to the Company certain previously advanced and unused funds.

Intellectual Property License A

Intellectual Property License Agreement and Sponsored Research Agreement	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intellectual Property License Agreement and Sponsored Research Agreement	Note 9 – Intellectual Property License Agreement and Sponsored Research Agreement Dartmouth College – IP License Agreement On October 2, 2019, the Company entered into the Intellectual Property License Agreement pursuant to which Dartmouth granted the Company an exclusive world-wide license under the patent application entitled “Mechanically Interlocked Molecules-based Materials for 3D Printing” in the field of human and animal health and certain additional patent rights to use and commercialize licensed products and services. The license grant includes the right of the Company to sublicense to third parties subject to the terms of the Agreement. The Agreement provided for: (i) a $ 25,000 500,000 Failure to timely make any payment due under the Agreement will result in interest charges to the Company of the lower of 10% per year or the maximum amount of interest allowable by applicable law. The Agreement may be terminated by Dartmouth if the Company is in material breach of the Agreement which is not cured after 30 days of notice thereof or if the Company becomes insolvent. Dartmouth may terminate the Agreement if the Company challenges a Dartmouth patent or does not terminate a sublicensee that challenges a Dartmouth patent, except in response to a valid court or governmental order. The Company may terminate the Agreement at any time upon six months written notice to Dartmouth. If the Company or any sublicensee or affiliate institutes or participates in a licensed patent challenge, the then current earned royalty rate for licensed products covered by Dartmouth patents will automatically be increased to three times the then current earned royalty rate. On March 23, 2021, the United States Patent and Trademark Office issued U.S. Patent No. 10,954,315 to the Trustees of Dartmouth College which is directed to mechanically interlocked, molecules-based materials for 3-D printing. The patent’s inventors are Professor Chenfeng Ke, a member of the Company’s Scientific Advisory Board and Qianming Lin, Professor Ke’s assistant. The patent grant is the culmination of the Intellectual Property License Agreement between the Company and Dartmouth with respect to an exclusive world-wide license of intellectual property related to 3D printable materials in the fields of human and animal health. The Company recorded $ 12,500 Dartmouth College – Sponsored Research Agreement On July 12, 2018, the Company entered into a one-year sponsored research agreement (the “Sponsored Research Agreement”) with the Trustees of Dartmouth College (“Dartmouth”) pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party will be owned by such party and intellectual property jointly invented or developed shall be jointly owned. On November 4, 2019, the parties entered into an amendment to the Sponsored Research Agreement which extended the term of the Agreement through July 14, 2020. The Sponsored Research Agreement expired by its terms in July 2020.

Commitments

Commitments	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments	Note 10 – Commitments (1) Science Advisory Board Member Consulting Agreements (the “ Consulting Agreements”) As part of its ongoing program of research and development, the Company has retained distinguished scientists and other qualified individuals to advise the Company with respect to its technology and business strategy and to assist it in the research, development and analysis of the Company’s technology and products. In furtherance thereof, the Company has retained certain Advisors as members of its Scientific Advisory Board and Business Advisory Board as described below, and the Company and Advisors have entered into Consulting Agreements with the following terms and conditions: - Scientific Advisory Board and Consulting Services - Advisor shall provide general consulting services to Company (the “Services”) as a member of its Scientific Advisory Board (“SAB”). As a member of the SAB, Advisor agrees to provide the Services as follows: (a) attending meetings of the Company’s SAB; (b) performing the duties of a SAB member at such meetings, as established from time to time by the mutual agreement of the Company and the SAB members, including without limitation meeting with Company employees, consultants and other SAB members, reviewing goals of the Company and assisting in developing strategies for achieving such goals, and providing advice, support, theories, techniques and improvements in the Company’s scientific research and product development activities; and (c) providing consulting services to Company at its request, including a reasonable amount of informal consultation over the telephone or otherwise as requested by Company. Advisor’s consultation with Company will involve services as scientific, technical and business advisor to the Company and its management with respect to neuronal injuries and neuro degenerative diseases. - SAB Consulting Compensation - the Company shall grant to Advisor the option to purchase certain number of shares of the common stock of the Company as per the stock option award grant. The options are subject to terms and provisions of the Company’s 2016 Stock Option and Stock Award Plan. (2) Business Advisory Board Agreements On February 10, 2020, the Company entered into a one-year advisory board member consulting agreement with Michael Maizel to serve on the Company’s Advisory Board as a business advisor. The Advisory Board Agreement automatically renews for up to two additional one-year periods, unless earlier terminated by either party upon 30 days’ prior written notice to the other party. In consideration for serving on the Advisory Board, the Company granted an option to purchase 50,000 25,000

Stock Plan

Stock Plan	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock Plan	Note 11 – Stock Plan 2016 Stock Option and Stock Award On December 14, 2016, the Board adopted the Company’s 2016 Stock Option and Stock Award Plan (the “Plan”). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Board. The Company has reserved 10 million shares for issuance under the Plan. (a) Stock Options granted to Science Advisors and Business Advisors On November 15, 2017, under the Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided that such Advisors are providing services to the Company at the time of exercise. 13,334 On April 16, 2018, under the Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the Advisor is providing services to the Company at the time of exercise. 10,000 On August 15, 2018, under the Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 6,667 shares of common stock, exercisable on August 15, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 6,667 shares of common stock exercisable on August 15, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 6,666 shares of common stock exercisable on August 15, 2020 at an exercise price of $2.00 per share, provided the Advisor is providing services to the Company at the time of exercise On July 1, 2019, under the Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 33,334 shares of common stock, exercisable on July 1, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on July 1, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on July 1, 2021 at an exercise price of $2.00 per share On February 10, 2020 under the Plan, the Company granted three-year options to purchase an aggregate of 50,000 shares of its common stock at an exercise price of $2.00 per share, to a Business Advisor (Note 10(2) above). 25,000 of such shares subject to the option were immediately exercisable and expire on February 10, 2023, and 25,000 shares vest on February 10, 2021 and expire on February 10, 2024 (b) On December 10, 2018, the Board awarded an employee the following three-year stock options under the Plan: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, provided the employee is providing services to the Company at the time of exercise On December 10, 2019, the Board awarded an employee, the following three-year stock options under the Plan: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2021 at an exercise price of $2.00 per share, provided the employee is providing services to the Company at the time of exercise On December 10, 2020, under the Plan, the Board awarded an employee, an immediately exercisable three-year stock option to purchase 100,000 2.00 The following table is the recognized compensation in respect of the above stock option compensation Three Months ended Six Months ended June 30, June 30, 2021 2020 2021 2020 Research and development expenses $ 3,100 $ 29,717 $ 6,200 $ 97,271 As of June 30, 2021 and December 31, 2020, total unrecognized compensation remaining to be recognized in future periods totaled $ 0 6,100 (c) Stock Options granted to Officers: On June 25, 2019, the Company appointed John N. Bonfiglio, PhD as its chief operating officer, effective July 1, 2019. As compensation, Dr. Bonfiglio was granted a three-year stock option to purchase 100,000 shares of common stock at an exercise price of $2.00 per share, 50,000 of which shares vested upon grant and 25,000 shares vest on each of July 1, 2020 and July 1, 2021, provided Dr. Bonfiglio is in the employ of the Company on such dates. On December 10, 2019, the Board granted five-year options to purchase 325,000 2.00 On December 10, 2020, the Board granted five-year options to purchase 325,000 2.00 There was no compensation recognized in the three and six months ended June 30, 2021 and 2020 related to stock option grants. As of June 30, 2021, and December 31, 2020, there was no unrecognized compensation remaining to be recognized in future periods. The fair value of each option award referenced above is estimated on the date of grant Measurement date Dividend yield 0% Expected volatility 114.69 ~ 186.80% Risk-free interest rate 0.39% ~ 2.68% Expected life (years) 3 ~ 5 Stock Price $0.38 ~ 2.80 Exercise Price $0.40 ~ 2.00 A summary of the activity for the Company’s stock options June 30, 2021 December 31, 2020 Weighted Average Weighted Average Remaining Contractual Life Weighted Average Weighted Average Remaining Contractual Life Shares Price (in years) Shares Price (in years) Outstanding, beginning of period 3,276,666 $ 2 3.28 2,515,000 $ 1.98 3.78 Granted - - - 800,000 $ 2 - Exercised - - - - $ - - Canceled/forfeited (85,000 ) $ 2 - (38,334 ) $ 2 - Outstanding, end of period 3,191,666 $ 2 3.08 3,276,666 $ 2 3.28 Options exercisable, end of period 3,191,666 $ 2 2.84 3,243,333 $ 2 3.28 Options expected to vest, end of period - $ - - 33,333 $ 2 2 Weighted average fair value of options granted $ 1.31 $ 1.31

Capital Stock

Capital Stock	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Capital Stock	Note 12 – Capital Stock Authorized: The Company has authorized 100,000,000 0.0001 10,000 0.001 Series A Preferred Stock: The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the “Stated Value”). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company’s common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on There was a total of 2,000 Common Stock In August 2020, the Company sold an aggregate of 200,000 100,000 There was a total of 13,289,789 Common Stock Purchase Warrants As of June 30, 2021 and December 31, 2020, the following common stock purchase warrants were outstanding Warrants Weighted Average Exercise Price Outstanding – December 31, 2019 70,000 (1) $ 1.00 Granted 110,000 (2)(3) 1.00 Canceled/forfeited - - Exercised - - Outstanding – December 31, 2020 180,000 1.00 Outstanding – December 31, 2020 180,000 1.00 Granted 115,000 (4) $ 1.00 Canceled/forfeited - - Exercised - - Outstanding –June 30, 2021 295,000 $ 1.00 (1) During the year ended December 31, 2019, the Company granted certain convertible notes holders warrants to purchase an aggregate of 70,000 1.00 36,410 (2) During the year ended December 31, 2020, the Company granted a convertible note holder a warrant to purchase 10,000 1.00 3,400 (3) Each two shares of common stock purchased in a private offering included one warrant to purchase an additional share of common stock at an exercise price of $1.00. (4) ) On June 15, 2021, the Company granted a convertible note holder a warrant to purchase 115,000 1.00 The fair value of the outstanding common stock purchase warrants Measurement date Dividend yield 0% Expected volatility 97.90~20.70% Risk-free interest rate 0.16 ~ 1.72% Expected life (years) 2.71 ~ 5.00 Stock Price $0.25 ~ $0.99 Exercise Price $0.40 ~ $1.00

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 13 – Subsequent Events The Company has evaluated events for the period from June 30, 2021 through the date of the issuance of these financial statements and determined that there are no additional events requiring disclosure.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Financial Statement Presentation:	Financial Statement Presentation: In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and six-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Fiscal Year End:	Fiscal Year End:
Use of Estimates:	Use of Estimates:
Cash Equivalents:	Cash Equivalents:
Research and Development Costs:	Research and Development Costs: Research and Development 23,186 174,459
Advertising and Marketing Costs:	Advertising and Marketing Costs: 15,000 23,500
Related Parties	Related Parties
Stock-Based Compensation and Other Share-Based Payments	Stock-Based Compensation and Other Share-Based Payments Compensation - Stock Compensation
Fair Value of Financial Instrument	Fair Value of Financial Instrument ASC 820, Fair Value Measurements Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of June 30, 2021: Liabilities Derivative liabilities $ $ $ 345,647 As of December 31, 2020: Liabilities Derivative liabilities $ - $ - $ 154,485
Warrants	Warrants Derivatives and Hedging
Income taxes	Income taxes Income Taxes
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Earnings Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the three and six months ended June 30, 2021 and 2020 include potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because the Company reported net income in the current three months ended June 30, 2021. As a result, the computations of net loss per share for each period reflected both basic and fully diluted loss per share. The table below reflects the potentially dilutive securities June 30, December 31, Research warrants at 3% of issued and outstanding shares 398 694 398 694 Convertible notes 634,966 445,400 Series A preferred shares 700 700 Stock options vested 3,191,666 3,243,333 Stock options not yet vested - 33,333 Stock purchase warrants 295,000 180,000 Total 4,521,026 4,301,460
New Accounting Pronouncements	New Accounting Pronouncements

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
summary of the fair value of the Company’s derivative liabilities	The following table provides a summary of the fair value of the Company’s derivative liabilities Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of June 30, 2021: Liabilities Derivative liabilities $ $ $ 345,647 As of December 31, 2020: Liabilities Derivative liabilities $ - $ - $ 154,485
The table below reflects the potentially dilutive securities	The table below reflects the potentially dilutive securities June 30, December 31, Research warrants at 3% of issued and outstanding shares 398 694 398 694 Convertible notes 634,966 445,400 Series A preferred shares 700 700 Stock options vested 3,191,666 3,243,333 Stock options not yet vested - 33,333 Stock purchase warrants 295,000 180,000 Total 4,521,026 4,301,460

Convertible Note _ Related Pa_2

Convertible Note – Related Party and Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Convertible Note Related Party And Derivative Liabilities
The carrying value of these convertible notes	The carrying value of these convertible notes June 30, December 31, Face value of certain convertible notes $ 25,000 $ 25,000 Carrying value $ 25,000 $ 25,000
Schedule of interest on the convertible note	Schedule of interest on the convertible note Three Months ended Six Months ended June 30, June 30, 2021 2020 2021 2020 Interest on the convertible notes $ 499 $ 501 $ 992 $ 1,003
the fair value of the derivative liability associated with the conversion feature	As a result of the application of ASC 815, the fair value of the derivative liability associated with the conversion feature Balance at December 31, 2019 $ 37,182 Change in fair value 24,500 Balance at December 31, 2020 61,682 Balance at December 31, 2020 61,682 Change in fair value (26,862 ) Balance at June 30, 2021 $ 34,820
The fair value at the commitment and re-measurement dates	The fair value at the commitment and re-measurement dates Commitment Date December 31, 2020 June 30, 2021 Expected dividends 0 0 0 Expected volatility 101% ~103% 316% ~ 333% 78% ~ 115% Expected term 0.92 ~ 1 year 0.74 year 0.25 year Risk free interest rate 1.33% 0.09% 0.05%

Convertible Note and Derivati_2

Convertible Note and Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Convertible Note And Derivative Liabilities
carrying value of these convertible note	The carrying value of these convertible note June 30, December 31, Face value of certain convertible notes $ 80,000 $ 80,000 Less: unamortized discount (18,600 ) (36,364 ) Carrying value $ 61,400 $ 43,636
Interest expenses associated with the convertible notes	Interest expenses associated with the convertible notes Three Months ended Six Months ended June 30, June 30, 2021 2020 2021 2020 Amortization on debt discount $ 8,931 $ 8,931 $ 17,764 $ 18,750 Interest on the convertible notes 1,895 1,895 2,569 3,381 Total $ 10,826 $ 10,826 $ 20,333 $ 22,131
the fair value of the derivative liability associated with the conversion feature	As a result of the application of ASC 815, as of June 30, 2021 and 2020, the fair value of the derivative liability associated with the conversion feature Balance at December 31, 2019 $ 52,185 Derivative addition associated with convertible notes 7,915 Change in fair value 32,703 Balance at December 31, 2020 92,803 Balance at December 31, 2020 92,803 Change in fair value 22,912 Balance at June 30, 2021 $ 115,715
the commitment and re-measurement dates for the Company’s derivative liabilities	The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities Commitment Date December 31, 2020 June 30, 2021 Expected dividends 0 0 0 Expected volatility 154% ~173% 280% ~296% 199%~358% Expected term 2.10 years 1.05 ~ 1.25 years 0.5 ~ 0.64 years Risk free interest rate 1.42 ~ 1.65% 0.10% 0.06%
The carrying value of the Note is as follows:	The carrying value of the Note is as follows: June 30, June 15, Face value of certain convertible notes $ 115,000 $ 115,000 Less: unamortized discount (110,274 ) (115,000 ) Carrying value $ 4,726 $ -
Interest expenses associated with the conversion is as follows:	Interest expenses associated with the conversion is as follows: Three Months ended Six Months ended June 30, June 30, 2021 2020 2021 2020 Amortization on debt discount $ 4,726 $ $ 4,726 $ Day one loss associated with derivative liability 79,332 79,332 Interest on the convertible notes 378 - 378 - Total $ 84,436 $ - $ 84,436 $ -
the fair value of the derivative liability associated with the conversion feature is summarized as follows:	As a result of the application of ASC 815 as of June 30, 2021 and June 15, 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows: Derivative liability associated with convertible note on commitment date $ 51,009 Derivative liability associated with warrants on commitment date 143,323 Derivative liability at June 15, 2021 194,332 Derivative liability at June 15, 2021 194,332 Change in fair value – convertible note 1,707 Change in fair value – warrants (927 ) Balance at June 30, 2021 $ 195,112
The fair value at the commitment and re-measurement	The fair value at the commitment and re-measurement Convertible note: Commitment Date June 30, Expected dividends 0 0 Expected volatility 307.10 % 312.60 % Expected term 1 years 0.96 years Risk free interest rate 0.18 % 0.23 % Warrants; Commitment Date June 30, Expected dividends 0 0 Expected volatility 201.70 % 200.60 % Expected term 5 years 4.96 years Risk free interest rate 0.65 % 0.66 %

Stock Plan (Tables)

Stock Plan (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
The following table is the recognized compensation in respect of the above stock option compensation	The following table is the recognized compensation in respect of the above stock option compensation Three Months ended Six Months ended June 30, June 30, 2021 2020 2021 2020 Research and development expenses $ 3,100 $ 29,717 $ 6,200 $ 97,271
The fair value of each option award referenced above is estimated on the date of grant	The fair value of each option award referenced above is estimated on the date of grant Measurement date Dividend yield 0% Expected volatility 114.69 ~ 186.80% Risk-free interest rate 0.39% ~ 2.68% Expected life (years) 3 ~ 5 Stock Price $0.38 ~ 2.80 Exercise Price $0.40 ~ 2.00
summary of the activity for the Company’s stock options	A summary of the activity for the Company’s stock options June 30, 2021 December 31, 2020 Weighted Average Weighted Average Remaining Contractual Life Weighted Average Weighted Average Remaining Contractual Life Shares Price (in years) Shares Price (in years) Outstanding, beginning of period 3,276,666 $ 2 3.28 2,515,000 $ 1.98 3.78 Granted - - - 800,000 $ 2 - Exercised - - - - $ - - Canceled/forfeited (85,000 ) $ 2 - (38,334 ) $ 2 - Outstanding, end of period 3,191,666 $ 2 3.08 3,276,666 $ 2 3.28 Options exercisable, end of period 3,191,666 $ 2 2.84 3,243,333 $ 2 3.28 Options expected to vest, end of period - $ - - 33,333 $ 2 2 Weighted average fair value of options granted $ 1.31 $ 1.31

Capital Stock (Tables)

Capital Stock (Tables)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
the following common stock purchase warrants were outstanding	As of June 30, 2021 and December 31, 2020, the following common stock purchase warrants were outstanding Warrants Weighted Average Exercise Price Outstanding – December 31, 2019 70,000 (1) $ 1.00 Granted 110,000 (2)(3) 1.00 Canceled/forfeited - - Exercised - - Outstanding – December 31, 2020 180,000 1.00 Outstanding – December 31, 2020 180,000 1.00 Granted 115,000 (4) $ 1.00 Canceled/forfeited - - Exercised - - Outstanding –June 30, 2021 295,000 $ 1.00
The fair value of the outstanding common stock purchase warrants	The fair value of the outstanding common stock purchase warrants Measurement date Dividend yield 0% Expected volatility 97.90~20.70% Risk-free interest rate 0.16 ~ 1.72% Expected life (years) 2.71 ~ 5.00 Stock Price $0.25 ~ $0.99 Exercise Price $0.40 ~ $1.00

summary of the fair value of th

summary of the fair value of the Company’s derivative liabilities (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Inputs, Level 1 [Member]
Liabilities
Derivative liabilities
Fair Value, Inputs, Level 2 [Member]
Liabilities
Derivative liabilities
Fair Value, Inputs, Level 3 [Member]
Liabilities
Derivative liabilities	$ 345,647	$ 154,485

The table below reflects the po

The table below reflects the potentially dilutive securities (Details) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,521,026	4,301,460
Research Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	398	398
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	634,966	445,400
Share-based Payment Arrangement [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	700	700
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,191,666	3,243,333
Stock Options Not Yet Vested [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		33,333
Stock Purchase Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	295,000	180,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Accounting Policies [Abstract]
Research and development costs	$ 11,350	$ 2,891	$ 23,186	$ 174,459
Advertising or marketing costs			$ 15,000	$ 23,500

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from loans	$ 100,000	$ 211,000

The carrying value of these con

The carrying value of these convertible notes (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Summary of Investment Holdings [Line Items]
Carrying value	$ 25,000	$ 25,000
Related Party Debt [Member]
Summary of Investment Holdings [Line Items]
Face value of certain convertible notes	25,000	25,000
Carrying value	$ 25,000	$ 25,000

Schedule of interest on the con

Schedule of interest on the convertible note (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Related Party Debt [Member]
Summary of Investment Holdings [Line Items]
Interest on the convertible notes	$ 499	$ 501	$ 992	$ 1,003

the fair value of the derivativ

the fair value of the derivative liability associated with the conversion feature (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Summary of Investment Holdings [Line Items]
Balance at December 31, 2020	$ 154,485
Balance at June 30, 2021	345,647	$ 154,485
Related Party Debt [Member]
Summary of Investment Holdings [Line Items]
Balance at December 31, 2020	61,682	37,182
Change in fair value	26,862	24,500
Balance at June 30, 2021	34,820	61,682
Change in fair value	(26,862)	(24,500)
Derivative Liabilitie [Member]
Summary of Investment Holdings [Line Items]
Balance at December 31, 2020	92,803	52,185
Balance at June 30, 2021	$ 115,715	$ 92,803

The fair value at the commitmen

The fair value at the commitment and re-measurement dates (Details) - Related Party Debt [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Summary of Investment Holdings [Line Items]
Expected dividends	0.00%	0.00%
Risk free interest rate	0.05%	0.09%
Commitment Date [Member]
Summary of Investment Holdings [Line Items]
Expected dividends	0.00%
Risk free interest rate	1.33%

Convertible Note _ Related Pa_3

Convertible Note – Related Party and Derivative Liabilities (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended
	Sep. 27, 2017	Sep. 01, 2016	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Received convertible note			$ 100,000	$ 10,000
Cubesquare Llc [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Ownership percentage		25.00%
Received convertible note	$ 15,000	$ 10,000
Interest rate per annum	8.00%	8.00%	8.00%
Conversionn description	Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare  into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare.	(i) $0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to  the average of the five  lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender
Accounts payable and accrued liabilities related party			$ 8,441		$ 7,449

carrying value of these convert

carrying value of these convertible note (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Summary of Investment Holdings [Line Items]
Carrying value	$ 25,000	$ 25,000
Derivative Liabilitie [Member]
Summary of Investment Holdings [Line Items]
Face value of certain convertible notes	80,000	80,000
Less: unamortized discount	(18,600)	(36,364)
Carrying value	$ 61,400	$ 43,636

Interest expenses associated wi

Interest expenses associated with the convertible notes (Details) - Derivative Liabilitie [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Summary of Investment Holdings [Line Items]
Amortization on debt discount	$ 8,931	$ 8,931	$ 17,764	$ 18,750
Interest on the convertible notes	1,895	1,895	2,569	3,381
Total	$ 10,826	$ 10,826	$ 20,333	$ 22,131

the commitment and re-measureme

the commitment and re-measurement dates for the Company’s derivative liabilities (Details) - Derivative Liabilitie [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Summary of Investment Holdings [Line Items]
Expected dividends	0.00%	0.00%
Commitment Date [Member]
Summary of Investment Holdings [Line Items]
Expected dividends	0.00%

The carrying value of the Note

The carrying value of the Note is as follows: (Details) - USD ($)	Jun. 30, 2021	Jun. 15, 2021	Dec. 31, 2020
Summary of Investment Holdings [Line Items]
Carrying value	$ 25,000		$ 25,000
Warrants [Member]
Summary of Investment Holdings [Line Items]
Face value of certain convertible notes	115,000	$ 115,000
Less: unamortized discount	(110,274)	(115,000)
Carrying value	$ 4,726

Interest expenses associated _2

Interest expenses associated with the conversion is as follows: (Details) - Warrants [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Summary of Investment Holdings [Line Items]
Amortization on debt discount	$ 4,726		$ 4,726
Day one loss associated with derivative liability	79,332		79,332
Interest on the convertible notes	378		378
Total	$ 84,436		$ 84,436

the fair value of the derivat_2

the fair value of the derivative liability associated with the conversion feature is summarized as follows: (Details) - Warrants [Member] - USD ($)	1 Months Ended
	Jul. 15, 2021	Jun. 30, 2021
Summary of Investment Holdings [Line Items]
Derivative liability at June 15, 2021	$ 51,009	$ 194,332
Derivative liability associated with warrants on commitment date	$ 143,323
Balance at June 30, 2021		195,112
Change in fair value – convertible note		1,707
Change in fair value – warrants		$ (927)

The fair value at the commitm_2

The fair value at the commitment and re-measurement (Details) - Warrants [Member]	6 Months Ended
	Jun. 30, 2021
Summary of Investment Holdings [Line Items]
Expected dividends	0.00%
Expected volatility	200.60%
Risk free interest rate	0.66%
Commitment Date [Member]
Summary of Investment Holdings [Line Items]
Expected dividends	0.00%
Expected volatility	201.70%
Risk free interest rate	0.65%
Convertible Notes Payable [Member]
Summary of Investment Holdings [Line Items]
Expected dividends	0.00%
Expected volatility	312.60%
Risk free interest rate	0.23%
Convertible Notes Payable [Member] | Commitment Date [Member]
Summary of Investment Holdings [Line Items]
Expected dividends	0.00%
Expected volatility	307.10%
Risk free interest rate	0.18%

Convertible Note and Derivati_3

Convertible Note and Derivative Liabilities (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended
	Feb. 19, 2020	Dec. 31, 2019	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Summary of Investment Holdings [Line Items]
Received convertible note			$ 100,000	$ 10,000
Derivative Liabilitie [Member]
Summary of Investment Holdings [Line Items]
Interest rate per annum	8.00%	8.00%
Received convertible note	$ 10,000	$ 70,000
Conversionn description	Such notes are convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) such other as the Company and the holder may agree.  In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 10,000 shares of common stock at an exercise price of $1.00.	convertible into shares of our common stock at a conversion price (the “Conversion Price”) for each share of common stock equal to the lesser of: (a) $0.50, (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable Notice of Conversion; and (c) so long as lower than (a) or (b), such price per share of common stock as the Company and the holder may agree from time to time.  In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00.
Accounts payable and accrued liabilities related party			9,942		$ 7,373
Derivative liability convertible notes			80,000
Derivative liabilities			$ 72,689

Unsecured Short-Term Advance _2

Unsecured Short-Term Advance from Third Party (Details Narrative) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Unsecured short term advance	$ 100,000	$ 100,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Sep. 27, 2017	Sep. 01, 2016
Related Party Transaction [Line Items]
Due to related party	$ 50,000		$ 50,000		$ 50,000
Cubesquare Llc [Member]
Related Party Transaction [Line Items]
Due to related party	$ 50,000		$ 50,000		10,000
Interest percentage	8.00%		8.00%				8.00%	8.00%
Interest expense	$ 997	$ 998	$ 1,983	$ 1,995
Accounts payable and accrued liabilities	8,657		8,657		6,674
Jonah Meer [Member]
Related Party Transaction [Line Items]
Due to related party	135,000		135,000		70,000
Accounts payable and accrued liabilities	22,993		22,993		28,475
Ido Merfeld [Member]
Related Party Transaction [Line Items]
Due to related party	50,000		50,000		$ 21,000	$ 1,169
Accounts payable and accrued liabilities	$ 1,169		$ 1,169

Intellectual Property License_2

Intellectual Property License Agreement and Sponsored Research Agreement (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
License fee		$ 25,000
Royalty expense		500,000
Licencee expense	$ 12,500	$ 12,500	$ 12,500

Commitments (Details Narrative)

Commitments (Details Narrative) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Feb. 10, 2020
Acquired Finite-Lived Intangible Assets [Line Items]
Number of options forfeited	85,000	38,334
Business Advisory Board Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Stock option and advisor granted			50,000
Number of options forfeited	25,000

The following table is the reco

The following table is the recognized compensation in respect of the above stock option compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Research and development expenses	$ 3,100	$ 29,717	$ 6,200	$ 97,271

The fair value of each option a

The fair value of each option award referenced above is estimated on the date of grant (Details)	6 Months Ended
	Jun. 30, 2021
Equity Option [Member] | Measurement Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%

summary of the activity for the

summary of the activity for the Company’s stock options (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Outstanding, beginning of period	3,276,666	2,515,000
Weighted Average Shares Exercise Price, Outstanding, beginning of period	$ 2	$ 1.98
Outstanding, Weighted Average Remaining Contractual Life	3 years 3 months 10 days	3 years 9 months 10 days
Shares, Granted		800,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 2
Shares, Exercised
Weighted Average Shares Exercise Price, Exercised
Shares, Canceled/forfeited	(85,000)	(38,334)
Weighted Average Exercise Price, Canceled/forfeited	$ 2	$ 2
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	3,191,666	3,276,666
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 2	$ 2
Shares Options exercisable, end of period	3,191,666	3,243,333
Weighted Average Exercise Price, Options exercisable, end of period	$ 2	$ 2
Options exercisable, Weighted Average Remaining Contractual Life	2 years 10 months 2 days	3 years 3 months 10 days
Shares, Options expected to vest, end of period		33,333
Weighted Average Exercise Price, Options expected to vest, end of period		$ 2
Options expected to vest, Weighted Average Remaining Contractual Life		2 years
Weighted Average Exercise Price, Weighted average fair value of options granted	$ 1.31	$ 1.31

Stock Plan (Details Narrative)

Stock Plan (Details Narrative) - USD ($)	Dec. 10, 2020	Feb. 10, 2020	Dec. 10, 2019	Dec. 10, 2018	Aug. 15, 2018	Jul. 31, 2019	Jun. 25, 2019	Apr. 16, 2018	Nov. 15, 2017	Jun. 30, 2021	Dec. 31, 2020
Stock Options Granted To Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Description of services agreement			(i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2021 at an exercise price of $2.00 per share, provided the employee is  providing services to the Company at the time of exercise	(i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, provided the employee is  providing services to the Company at the time of exercise
Granted an option to purchase of common stock	100,000
Weighted average excercise price	$ 2
Unrecognized compensation										$ 0	$ 6,100
Stock Options Granted To Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Description of services agreement							As compensation, Dr. Bonfiglio was granted a three-year stock option to purchase 100,000 shares of common stock at an exercise price of $2.00 per share, 50,000 of which shares vested upon grant and 25,000 shares vest on each of July 1, 2020 and July 1, 2021, provided Dr. Bonfiglio is in the employ of the Company on such dates.
Granted an option to purchase of common stock	325,000		325,000
Weighted average excercise price	$ 2		$ 2
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Description of services agreement		the Company granted three-year options to purchase an aggregate of 50,000 shares of its common stock at an exercise price of $2.00 per share, to a Business Advisor (Note 10(2) above). 25,000 of such shares subject to the option were immediately exercisable and expire on February 10, 2023, and 25,000 shares vest on February 10, 2021 and expire on February 10, 2024			the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 6,667 shares of common stock, exercisable on August 15, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 6,667 shares of common stock exercisable on August 15, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 6,666 shares of common stock exercisable on August 15, 2020 at an exercise price of $2.00 per share, provided the Advisor is  providing services to the Company at the time of exercise	the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 33,334 shares of common stock, exercisable on July 1, 2019 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on July 1, 2020 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on July 1, 2021 at an exercise price of $2.00 per share		the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the Advisor is  providing services to the Company at the time of exercise.	the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided that such Advisors are providing services to the Company at the time of exercise.
Number of option expired									13,334
Option vested								10,000

the following common stock purc

the following common stock purchase warrants were outstanding (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Equity [Abstract]
Warrants Outstanding Beginning	180,000	70,000
Weighted Average Exercise Price Outstanding Beginning	$ 1	$ 1
Warrants Granted	115,000	110,000
Weighted Average Exercise Price Granted	$ 1	$ 1
Warrants Canceled/Forfeited
Weighted Average Exercise Price Canceled/Forfeited
Warrants Exercised
Weighted Average Exercise Price Exercised
Warrants Outstanding Enfing	295,000	180,000
Weighted Average Exercise Price Outstanding Ending	$ 1	$ 1

The fair value of the outstandi

The fair value of the outstanding common stock purchase warrants (Details)	6 Months Ended
	Jun. 30, 2021
Warrant [Member] | Measurement Date [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Dividend yield	0.00%

Capital Stock (Details Narrativ

Capital Stock (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 15, 2021	Aug. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2021
Equity [Abstract]
Common Stock, Shares Authorized			100,000,000		100,000,000
Common Stock, Par or Stated Value Per Share			$ 0.0001		$ 0.0001
Preferred Stock, Shares Authorized			10,000		10,000
Preferred Stock, Par or Stated Value Per Share			$ 0.001		$ 0.001
Preferred Stock, Shares Issued			2,000		2,000
Preferred Stock, Shares Outstanding			2,000		2,000
Number of shares sold to investers in private offering		200,000
Gross proceeds from investors		$ 100,000
Common Stock, Shares, Issued			13,289,789		13,289,789
Common Stock, Shares, Outstanding			13,289,789		13,289,789
Number of common shares issued for warrants	115,000		10,000	70,000
Share price per share	$ 1		$ 1	$ 1
Number of common shares issued for warrants amount			$ 3,400	$ 36,410